ClinicalTrials.gg
CompletedNCT01147809Updated Apr 18, 2016Results posted

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

A Phase 2 interventional study of Eltrombopag olamine and Placebo in Thrombocytopaenia, sponsored by GlaxoSmithKline. Completed at 86 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-18.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.

Enrollment
10th of 53
130 · median 40
Started
2010
with 3 others
Phase 2
27 of 53
2 open now
Registered
20th of 53
by date
Lead sponsor
16 of 53
GlaxoSmithKline

Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 10th largest by enrollment, is one of 4 that started in 2010, is one of 27 in phase 2, and was the 20th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing eltrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.

03

Conditions studied

  • Thrombocytopaenia

Browse trials for

Keywords

  • Solid Tumor
  • Eltrombopag
  • chemotherapy-induced thrombocytopenia
  • Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Inclusion Criteria Subjects eligible for enrolment in Phase I and II of the study must meet all of the following criteria:

  • Signed written .
  • Age ≥ 18 years.
  • Subjects with confirmed solid tumor and scheduled to receive at least two cycles of either gemcitabine monotherapy OR gemcitabine in combination with carboplatin or cisplatin at the same dosages and schedule in the study. Novel anticancer agents (e.g. bevacizumab, erlotinib) may be allowed if considered a standard treatment by the investigator. Subjects with only ONE current diagnosis of primary solid tumor will be allowed into the study.
  • Note: For patients scheduled to receive any novel anticancer agents (e.g. bevacizumab, erlotinib), consultation and approval from the GSK medical monitor should occur before the subject is enrolled into the study.
  • of at least 3 months, in the opinion of the investigator.
  • -Zubrod performance status ≤ 2
  • For Phase I: Pre-chemotherapy count ≤ 300 Gi/L in the screening period before the subject start their first planned cycle of treatment with gemcitabine monotherapy OR gemcitabine in combination with carboplatin or cisplatin in the study.
  • For Phase II (Part 1 and 2): Subjects must meet one of the following platelet count entry criteria:

    1. Subjects have not started the first cycle in this disease setting and have a platelet count \< 150 Gi/L in the screening period as measured within 3 days before Day -5, OR
    2. Subjects started chemotherapy for this disease setting and had platelet count \< 150 Gi/L on Day 1 in the preceding cycle before entry into the study, OR
    3. Platelet count \< 100 Gi/L at Day 8 in the preceding cycle before entry into the study, OR
    4. Platelet count \< 100 Gi/L at Day 15 in the preceding cycle before entry into the study (for subjects receiving Gemcitabine monotherapy) Note: For any of these platelet counts, a repeated platelet count may be allowed only once to ensure that the subject meets the above platelet count criteria and the latest count will be taken for the assessment of eligibility to the study..
  • Subjects with previous chemotherapy treatment in a previous disease setting are allowed provided they have recovered from chemotherapy related toxicity except alopecia (and the lab parameters mentioned in Inclusion criteria in #9).
  • Adequate organ function during screening period defined by the criteria below (adequate baseline organ function):
  • SYSTEM LABORATORY VALUES
  • Hematologic
  • Platelets, see Inclusion criteria
  • (absolute neutrophil count) ≥1.5 × 109/L
  • ≥9 g/dL
  • (PT/INR) and activated partial thromboplastin time (aPTT) Within 80 to 120% of the normal range
  • Hepatic
  • Albumin ≥2.5 g/dL
  • Serum ≤1.5 x and ALT

    • 3 × ULN without liver
    • 5 × ULN if documented liver metastases
  • Renal
  • Serum Creatinine ≤ 1.2 x ULN
  • Subjects with AST, ALT or bilirubin values outside the range(s) in the table due to Gilbert's syndrome or asymptomatic gall stones are not excluded.
  • Women of must have a negative serum pregnancy test within 2 weeks prior to randomization and agree to use effective , during the study and for 4 weeks following the last dose of product.
  • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from 2 weeks prior to randomization until 13 weeks after the last dose of study treatment.
  • Able to swallow and retain orally administered medication and does not have any gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • Lactating females.
  • Pre-existing cardiovascular disease (congestive heart failure, [NYHA] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), unstable angina, or subjects with a >450 msec (QTc >480 msec for subjects with Bundle Branch Block) at study entry, or myocardial infarction within the preceding 6 months. Subjects with a34 pacemaker or defibrillator are not excluded provided that their cardiac function is within normal ranges.
  • Note: For patients with pre-existing NYHA Grade II cardiovascular disease, the investigator should consult with GSK medical monitor before enrolling the subject into the study.
  • Patients with known factor V leiden, antiphospholipid antibody syndrome, prothrombin gene mutations, ATIII deficiency, protein C deficiency, protein S deficiency OR recent history of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism) within the preceding 6 months.
  • Note: for patients with known risk factors for thromboembolism e.g., diabetes, hypercholesterolemia, recent major surgery etc., the investigator should consult with GSK medical monitor before enrolling the patient into the study and all risk factors should be documented in the CRF.
  • Prior surgery within two weeks before study randomization or radiotherapy (RT) within four weeks before study randomization. Subjects with prior surgery or RT are not permitted into the study unless they have completely recovered from surgery and/or acute RT toxicity except for alopecia.
  • Note: Note: patients with minor surgeries or outpatient procedures (e.g. insertion of central venous catheter) are immediately allowed in the study provided that there were no complications from the procedure or surgery.
  • History of prior radiotherapy to more than 20% bone marrow bearing sites.
  • History of platelet agglutination abnormality, platelet disorders or dysfunction or bleeding disorder that prevents reliable measurement of platelet counts.
  • Subjects with a history of or clinical signs or symptoms of brain and/or confirmed by CT or MRI brain scan unless properly treated. Subjects with CNS metastases treated by neurosurgical resection or brain performed within 3 months prior to randomization will be excluded.
  • Treated brain metastases are defined
  • Having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed.
  • Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician.

Note: if subject has performed a CT scan immediately prior to the screening period and CT could not be repeated, an MRI should be performed in the screening period to exclude the development of brain metastases and/or the progression of the pre-existing brain metastatic lesion(s).

  • Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of investigational product in the study. Concurrent participation in another interventional clinical trial or administration of any investigational drug during the study is also not permitted.
  • A known immediate or delayed reaction or idiosyncrasy that, in the opinion of the Investigator or GSK Medical Monitor is due to drugs chemically related to eltrombopag or (e.g. mannitol).
  • Subjects with known , or (HIV). Subjects with Gilbert's Syndrome are permitted into the study.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Active comparator
    Eltrombopag

    Drug: eltrombopag olamine thrombopoietin receptor agonist

    Drug: Eltrombopag olamine

  • Placebo comparator
    Placebo

    Other: Placebo Placebo tablets with no active pharmaceutical ingredient

    Other: Placebo

Interventions

  • thrombopoietin receptor agonist

  • OtherPlacebo

    Placebo tablets with no active pharmaceutical ingredient

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I

    AEs are coded using the standard Medical Dictionary for Regulatory Activities (MedDRA) and were graded by the investigator according to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), version 4.0. AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.

    Time frame: From Cycle 1, Day 1 (C1D1) until at least 30 days post-investigational product discontinuation (longer for AEs considered related to study participation)

  2. Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I

    Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), lymphocytes (decreased), total absolute neutrophil count (ANC), platelets (PLT) and white blood cells (WBC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participant available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

    Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up

  3. Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I

    Clinical chemistry laboratory parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Clinical chemistry laboratory parameters included albumin (Alb), urea/blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total bilirubin (TB), direct bilirubin (DB) and international normalized ratio/Prothrombin time (PT). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

    Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up

  4. Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I

    The number of participants with at least 1 change from Baseline in creatinine, with an increase \>=26.5 UMOL/L are reported. Creatinine clearance is estimated using the Cockcroft-Gault formula which is a method to approximate kidney function. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1.

    Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up

  5. Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I

    ECOG-Zubrod scores for the performance status are defined as follows: Score 0: Fully active, 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: ambulatory and capable of all self-care but unable to carry out any work activities, 3: capable of only limited self-care, 4: completely disabled, 5: dead. The data is presented for the participants with the ECOG performance score at the indicated time points during the study.

    Time frame: Screening, C1D1, C2D1, C2D8, C2D15, C3D1, C4D1, C4D22, C5D1, C5D8, C6D1, C6D15

  6. Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I

    A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and post-dose on C2D4. Three further ECGs were carried out at C2D8, C5D8 and C6D15. Change in ECG findings were categorized as 'Clinically significant change: favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Any time post-Baseline is defined by counting the participants under the worst result experienced post-Baseline. The best to worst order is 'Clinically significant change: favorable', 'No change or insignificant change', and then 'Clinically significant change (CSC): unfavorable. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

    Time frame: C2D4, C2D8, C5D8, C6D15

  7. Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II

    Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each participant across Cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), Baseline loge(platelet count) and part of study (part 1 or 2 of phase II). Only those participants available at indicated time points were analyzed (represented by n=X,X).

    Time frame: Day 1 (averaged across cycles 1 to 6)

Secondary outcomes

  1. Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I

    Pre-chemotherapy platelet count is defined for Cycle 1 as the platelet count (from central laboratory data) immediately preceding the first dose of chemotherapy within Cycle 1. For all subsequent cycles it is defined as the platelet count (from central laboratory data) immediately preceding, but limited to within 2 days prior to the first dose of chemotherapy at Day 1. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at the following time points: Group A; Days 1 and 8 of Cycles 1 to 6. Group B; Days 1, 8 and 15 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

    Time frame: C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1,C4D8, C4D15, C5D1,C5D8, C5D15, C6D1,C6D8 and C6D15

  2. Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I

    Within-subject platelet count for each participant was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the participant had data. The average within a treatment group was calculated by summing up the values from each participant within the treatment group and dividing it by the number of participants. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 2 to 6 are summarized. Blood samples were collected on Days 1 and 8 of Cycles 2 to 6 for Group A and on Days 1, 8 and 15 from Cycles 2 to 6 for Group B to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

    Time frame: Day 1 (averaged across Cycles 2 to 6), Day 8 (averaged across Cycles 2 to 6)

  3. Platelet Count Nadir for Each Chemotherapy Cycle in Phase I

    Platelet nadir is defined as the lowest platelet count (from central laboratory data) reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 and 2, at Days 1, 4, 8, 15 and 17 of Cycle 3 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

    Time frame: Cycle 1 to Cycle 6

  4. Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I

    The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 2 to 6. For 21-Day Cycle, the chemotherapy cycle consisted of 21 days and for 28-Day Cycle, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-Day Cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-Day Cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.

    Time frame: All assessments from Cycle 2 Day 1 to last assessment in Cycle 6

  5. Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count

    As per the CTCAE version 4.0, par. with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; par. with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; par. with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and par. with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Par. experiencing thrombocytopenia (Platelets \<150Gi/L) at least once within a cycle are presented in the category title as n=X,X,X,X.

    Time frame: Cycle 1 to Cycle 6

  6. Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts

    Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for Group A was 21 days and for Group B was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.

    Time frame: Cycle 2 to Cycle 6

  7. Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I

    Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

    Time frame: Cycle 1 to Cycle 6

  8. Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts

    Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. Time to recovery (TR) (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22, and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

    Time frame: Cycle 1 to Cycle 6

  9. Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I

    Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: Cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within Cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on electronic case report form (eCRF).

    Time frame: Cycle 1 to Cycle 6

  10. Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I

    Any delay in a scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants.

    Time frame: All time on chemotherapy treatment

  11. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II

    AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.

    Time frame: From first dose of investigational product (IP) until 30 days after discontinuation of IP (Longer for AEs related to study participation)

  12. Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II

    The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were further classified into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline is defined as the Day 1 assessment or the latest possible screening assessment. Across Cycles 1-6 included all assessments after first dose of chemotherapy up to the end of Cycle 6. Data exclused for participants taking drugs that affect platelet function or anticoagulants, from the time that the medication was started.

    Time frame: Screening, Day -5, Day 1 and 8 of Cycles 1 to 6 of 21-day cycle schedule, Day 1, 8 and 15 of cycles 1 to 6 of 28-day schedule, treatment withdrawal and 30-day follow-up

  13. Number of Participants Requiring a Platelet Transfusion in Phase II

    Platelet transfusion was used as a rescue medication for the treatment of thrombocytopenia. Number of participants requiring a platelet transfusion during Cycles 1-6 was summarized and compared between treatment groups using a logistic regression model adjusted for cycle duration. Each cycle included assessments starting at Day 1 of the cycle.

    Time frame: Screening, Day -5, throughout cycles 1 to 6 and up to 30 days after IP discontinuation

  14. Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

    Any delay in scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants. Number of participants with any delay in dose during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only those participants who actually received chemotherapy are included for the cisplatin and carboplatin components and all participants are included for the gemcitabine components (represented by n=X,X in the category titles).

    Time frame: Cycle 1 to Cycle 6

  15. Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

    Dose reductions are required following potential drug-related toxicities. Number of participants with any dose reduction during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only participants who actually received chemotherapy were included for the cisplatin and carboplatin components. All participants were included for the gemcitabine components.

    Time frame: Cycle 1 to Cycle 6

  16. Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II

    Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on eCRF. The average chemotherapy dose intensity at Day 1 across Cycles 1 to 6, Day 8 across Cycles 1 to 6 and Day 15 across Cycles 1 to 6 was summarized and compared between treatment groups using an ANCOVA model adjusted for cycle duration and part of the study.

    Time frame: Cycle 1 to Cycle 6

  17. Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II

    Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included Hemoglobin (Hb) increased, Anemia, Lymphocyte count (Lym), platelet count, White Blood Cell count (WBC) and Total Absolute Neutrophil Count (Total ANC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. participants with missing Baseline value were assumed to have normal Baseline value. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).

    Time frame: After baseline (C1D1), on-treatment and 30 day follow-up

  18. Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II

    Clinical chemistry laboratory parameters with a related CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Worst-case grade change of the laboratory parameters at anytime post-Baseline is presented as "Any grade increase", "Increase to Grade 3 or Grade 4". Clinical chemistry laboratory parameters included Albumin (Al), creatinine, AST, ALT, ALP, TB, Calcium hypercalcemia (CaHy)/hypocalcemia (CaHo), Glucose hyperglycemia (GluHy)/hypoglycemia (GluHo), Potassium hypernatremia (KHy)/hyponatremia (KHo) and Sodium hypernatremia (NaHy)/hyponatremia (NaHo). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).

    Time frame: After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up

  19. Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II

    Number of participants with at least 1 assessment of change from Baseline in creatinine, with increase \>=26.5 UMOL/L are presented. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of IP.

    Time frame: After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up

  20. Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II

    ECOG-Zubrod scores for the Performance Status were defined as follows: 0: Fully active, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: Ambulatory and capable of all self-care but unable to carry out any work activities, 3: Capable of only limited self-care, 4: Completely disabled, 5 and Unknown: Dead. The data is presented for the participants with the ECOG performance score at different time points during the study. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

    Time frame: Screening, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1 and C17D1

  21. Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II

    A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and 2 to 6 hours post-dose on C1D4. Change in ECG findings were categorized as 'Clinically significant change (CSC): favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of investigational product. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

    Time frame: C1D4

  22. Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

    Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 8 scheduled platelet count.

    Time frame: Day 8 (averaged across cycles 1 to 6)

  23. Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

    Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 15 scheduled platelet count.

    Time frame: Day 15 (averaged across cycles 1 to 6)

  24. Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II

    Within-subject platelet count for each par. was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the par. had data. The average within a treatment group was calculated by summing up the values from each par. within the treatment 21-day cycle dividing it by the number of par. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 1 to 6 are summarized. Blood samples were collected on Day 1 and 8 of Cycles 1 to 6 for 21-day cycle and on Day 1, 8 and 15 from Cycles 1 to 6 for 28-day cycle to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

    Time frame: Day 1, Day 8, Day 15 (all averaged across cycles 1 to 6)

  25. Platelet Count Nadir for Each Chemotherapy Cycle in Phase II

    Platelet nadir is defined as the lowest platelet count reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Day 1, Day 4, Day 8, Day 15 and Day 17 of Cycles 1 to 6. 28-day cycle; Day 1, Day 4, Day 8, Day 15, Day 22, Day 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).

    Time frame: Cycle 1 to Cycle 6

  26. Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II

    The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 1 to 6. Blood samples were collected to estimate platelet count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.

    Time frame: All assessments from Cycle 1 Day 1 to last assessment in Cycle 6

  27. Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II

    As per the CTCAE version 4.0, participants with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; participants with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; participants with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and participants with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Participants experiencing thrombocytopenia(Platelets \<150Gi/L) at least once within cycle are presented in the category title as n=X,X.

    Time frame: Cycle 1 to Cycle 6

  28. Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II

    Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for 21-day cycle was 21 days and for 28-day cycle was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.

    Time frame: Cycle 1 to Cycle 6

  29. Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II

    Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).

    Time frame: Cycle 1 to Cycle 6

  30. Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II

    Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. TR (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. Blood samples were collected to estimate platelet count at: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22, and 24of Cycles 1 to 6. Time to recover censored if platelet count did not return to \>=100/150 Gi/L. Censored results are excluded from calculation of summary statistics. Only those participants available at indicated time points were analyzed (represented by n=X, X).

    Time frame: Cycle 1 to Cycle 6

07

Results

Posted Apr 18, 2016

Participant flow

Participants (par.) with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin were eligible for enrollment into the study. The study comprised of 2 phases (I \& II), with eligible par. being randomized to receive placebo or eltrombopag in each phase.

Phase I (168 Days)
Participant flow — Phase I (168 Days)
MilestonePhase I: 21-Day Cycle PlaceboPhase I: 21-Day Cycle Eltrombopag 100 mgPhase I: 28-Day Cycle PlaceboPhase I: 28-Day Cycle Eltrombopag 100 mgPhase II: PlaceboPhase II: Eltrombopag 100 mg
Started3941000
Completed282500
Not completed112500
Withdrew: Adverse event000100
Withdrew: Lost to follow-up100100
Withdrew: Physician decision012000
Withdrew: Withdrawal by subject000300
Phase II (168 Days)
Participant flow — Phase II (168 Days)
MilestonePhase I: 21-Day Cycle PlaceboPhase I: 21-Day Cycle Eltrombopag 100 mgPhase I: 28-Day Cycle PlaceboPhase I: 28-Day Cycle Eltrombopag 100 mgPhase II: PlaceboPhase II: Eltrombopag 100 mg
Started00002352
Ongoing000010
Completed0000719
Not completed00001633
Withdrew: Adverse event000036
Withdrew: Protocol violation000001
Withdrew: Physician decision0000511
Withdrew: Withdrawal by subject0000715
Withdrew: Ongoing000010

Outcome measures

PrimaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I

AEs are coded using the standard Medical Dictionary for Regulatory Activities (MedDRA) and were graded by the investigator according to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), version 4.0. AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.

Time frame:
From Cycle 1, Day 1 (C1D1) until at least 30 days post-investigational product discontinuation (longer for AEs considered related to study participation)
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Any AE Pre-therapy3849
Any SAE Pre-therapy1001
Any AE On-therapy+30 days39310
Any SAE On-therapy+30 days1512
Any AE Post-therapy0003
Any SAE Post-therapy0001
Treatment-related AEs On-therapy+30 days2316
>=Grade 3 AEs On-therapy+30 days2723
Liver AEs On-therapy+30 days0202
Renal AEs On-therapy+30 days0320
Thromboembolic events On-therapy+30 days0201
Cardiac AEs On-therapy+30 days0111
Neutropenia On-therapy+30 days3425
Anemia On-therapy+30 days1414
Thrombocytopenia On-therapy+30 days2333
Leukopenia On-therapy+30 days1223
Thrombocytosis On-therapy+30 days2212
Platelet count increased On-therapy+30 days0003
PrimaryNumber of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I

Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), lymphocytes (decreased), total absolute neutrophil count (ANC), platelets (PLT) and white blood cells (WBC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participant available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame:
After Baseline (C1D1), on-treatment and 30 day follow-up
Reported as:
Number · Participants
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Hemoglobin (Increased), Grade 0, n=3,9,4,1039410
Hemoglobin (Anemia), Grade 1, n=3,9,4,102103
Hemoglobin (Anemia), Grade 2, n=3,9,4,100624
Hemoglobin (Anemia), Grade 3, n=3,9,4,101223
Lymphocytes (Increased), Grade 0, n=3,9,4,1038410
Lymphocytes (Increased), Grade 2, n=3,9,4,100100
Lymphocytes (Decreased), Grade 0, n=3,9,4,101103
Lymphocytes (Decreased), Grade 1, n=3,9,4,100200
Lymphocytes (Decreased), Grade 2, n=3,9,4,101114
Lymphocytes (Decreased), Grade 3, n=3,9,4,101532
Lymphocytes (Decreased), Grade 4, n=3,9,4,100001
Total ANC, Grade 0, n=1,2,1,20210
Total ANC, Grade 1, n=1,2,1,21002
PLT, Grade 0, n=3,9,4,100102
PLT, Grade 1, n=3,9,4,100113
PLT, Grade 2, n=3,9,4,100313
PLT, Grade 3, n=3,9,4,101221
PLT, Grade 4, n=3,9,4,102201
WBC, Grade 0, n=3,9,4,100012
WBC, Grade 1, n=3,9,4,100102
WBC, Grade 2, n=3,9,4,102212
WBC, Grade 3, n=3,9,4,101523
WBC, Grade 4, n=3,9,4,100101
PrimaryNumber of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I

Clinical chemistry laboratory parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Clinical chemistry laboratory parameters included albumin (Alb), urea/blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total bilirubin (TB), direct bilirubin (DB) and international normalized ratio/Prothrombin time (PT). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame:
After Baseline (C1D1), on-treatment and 30 day follow-up
Reported as:
Number · Participants
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Alb, Grade 0, n=3,9,4,102404
Alb, Grade 1, n=3,9,4,101225
Alb, Grade 2, n=3,9,4,100311
Alb, Grade 3, n=3,9,4,100010
ALP, Grade 0, n=3,9,4,102336
ALP, Grade 1, n=3,9,4,101511
ALP, Grade 2, n=3,9,4,100102
ALP, Grade 3, n=3,9,4,100001
ALT, Grade 0, n=3,9,4,102334
ALT, Grade 1, n=3,9,4,101415
ALT, Grade 2, n=3,9,4,100200
ALT, Grade 3, n=3,9,4,100001
AST, Grade 0, n=3,9,4,102425
AST, Grade 1, n=3,9,4,101323
AST, Grade 2, n=3,9,4,100101
AST, Grade 3, n=3,9,4,100101
TB, Grade 0, n=3,9,4,103538
TB, Grade 1, n=3,9,4,100200
TB, Grade 2, n=3,9,4,100210
TB, Grade 3, n=3,9,4,100002
Ca (hypercalcemia), Grade 0, n=3,9,4,1038410
Ca (hypercalcemia), Grade 1, n=3,9,4,100100
Ca (hypercalcemia), Grade 2, n=3,9,4,100000
Ca (hypercalcemia), Grade 3, n=3,9,4,100000
Ca (hypocalcemia), Grade 0, n=3,9,4,102739
Ca (hypocalcemia), Grade 1, n=3,9,4,101100
Ca (hypocalcemia), Grade 2, n=3,9,4,100111
Ca (hypocalcemia), Grade 3, n=3,9,4,100000
Creatinine, Grade 0, n=3,9,4,103749
Creatinine, Grade 1, n=3,9,4,100101
Creatinine, Grade 2, n=3,9,4,100100
Creatinine, Grade 3, n=3,9,4,100000
Glu (hyperglycemia), Grade 0, n=3,9,4,102312
Glu (hyperglycemia), Grade 1, n=3,9,4,100424
Glu (hyperglycemia), Grade 2, n=3,9,4,101214
Glu (hyperglycemia), Grade 3, n=3,9,4,100000
Glu (hypoglycemia), Grade 0, n=3,9,4,103848
Glu (hypoglycemia), Grade 1, n=3,9,4,100001
Glu (hypoglycemia), Grade 2, n=3,9,4,100101
Glu (hypoglycemia), Grade 3, n=3,9,4,100000
K (hyperkalemia), Grade 0, n=3,9,4,101839
K (hyperkalemia), Grade 1, n=3,9,4,102100
K (hyperkalemia), Grade 2, n=3,9,4,100011
K (hyperkalemia), Grade 3, n=3,9,4,100000
K (hypokalemia), Grade 0, n=3,9,4,102537
K (hypokalemia), Grade 1, n=3,9,4,101313
K (hypokalemia), Grade 2, n=3,9,4,100000
K (hypokalemia), Grade 3, n=3,9,4,100100
Na (hypernatremia), Grade 0, n=3,9,4,1029310
Na (hypernatremia), Grade 1, n=3,9,4,101010
Na (hypernatremia), Grade 2, n=3,9,4,100000
Na (hypernatremia), Grade 3, n=3,9,4,100000
Na (hyponatremia), Grade 0, n=3,9,4,102425
Na (hyponatremia), Grade 1, n=3,9,4,101405
Na (hyponatremia), Grade 2, n=3,9,4,100000
Na (hyponatremia), Grade 3, n=3,9,4,100120
PrimaryNumber of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I

The number of participants with at least 1 change from Baseline in creatinine, with an increase \>=26.5 UMOL/L are reported. Creatinine clearance is estimated using the Cockcroft-Gault formula which is a method to approximate kidney function. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1.

Time frame:
After Baseline (C1D1), on-treatment and 30 day follow-up
Reported as:
Number · Participants
Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I0312
PrimaryNumber of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I

ECOG-Zubrod scores for the performance status are defined as follows: Score 0: Fully active, 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: ambulatory and capable of all self-care but unable to carry out any work activities, 3: capable of only limited self-care, 4: completely disabled, 5: dead. The data is presented for the participants with the ECOG performance score at the indicated time points during the study.

Time frame:
Screening, C1D1, C2D1, C2D8, C2D15, C3D1, C4D1, C4D22, C5D1, C5D8, C6D1, C6D15
Reported as:
Number · Participants
Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Screening, Score 0, n=3,9,4,103513
Screening, Score 1, n=3,9,4,100337
Screening, Score 2, n=3,9,4,100100
Screening, Score 3, n=3,9,4,100000
C1D1, Score 0, n=3,9,4,103523
C1D1, Score 1, n=3,9,4,100327
C1D1, Score 2, n=3,9,4,100100
C1D1, Score 3, n=3,9,4,100000
C2D1, Score 0, n=3,8,4,101322
C2D1, Score 1, n=3,8,4,101418
C2D1, Score 2, n=3,8,4,101110
C2D1, Score 3, n=3,8,4,100000
C2D8, Score 0, n=1,0,1,01NA0NA
C2D8, Score 1, n=1,0,1,00NA0NA
C2D8, Score 2, n=1,0,1,00NA1NA
C2D8, Score 3, n=1,0,1,01NA0NA
C2D15, Score 0, n=0,1,0,1NA0NA0
C2D15, Score 1, n=0,1,0,1NA0NA1
C2D15, Score 2, n=0,1,0,1NA1NA0
C2D15, Score 3, n=0,1,0,1NA0NA0
C3D1, Score 0, n=2,6,2,71224
C3D1, Score 1, n=2,6,2,71203
C3D1, Score 2, n=2,6,2,70100
C3D1, Score 3, n=2,6,2,70100
C4D1, Score 0, n=2,6,1,71104
C4D1, Score 1, n=2,6,1,71313
C4D1, Score 2, n=2,6,1,70100
C4D1, Score 3, n=2,6,1,70100
C4D22, Score 0, n=0,0,0,1NANANA0
C4D22, Score 1, n=0,0,0,1NANANA0
C4D22, Score 2, n=0,0,0,1NANANA1
C4D22, Score 3, n=0,0,0,1NANANA0
C5D1, Score 0, n=1,3,1,40002
C5D1, Score 1, n=1,3,1,41112
C5D1, Score 2, n=1,3,1,40100
C5D1, Score 3, n=1,3,1,40100
C5D8, Score 0, n=0,1,0,0NA0NANA
C5D8, Score 1, n=0,1,0,0NA0NANA
C5D8, Score 2, n=0,1,0,0NA0NANA
C5D8, Score 3, n=0,1,0,0NA1NANA
C6D1, Score 0, n=1,1,1,40102
C6D1, Score 1, n=1,1,1,41012
C6D1, Score 2, n=1,1,1,40000
C6D1, Score 3, n=1,1,1,40000
C6D15, Score 0, n=0,0,0,1NANANA0
C6D15, Score 1, n=0,0,0,1NANANA1
C6D15, Score 2, n=0,0,0,1NANANA0
C6D15, Score 3, n=0,0,0,1NANANA0
PrimaryNumber of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I

A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and post-dose on C2D4. Three further ECGs were carried out at C2D8, C5D8 and C6D15. Change in ECG findings were categorized as 'Clinically significant change: favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Any time post-Baseline is defined by counting the participants under the worst result experienced post-Baseline. The best to worst order is 'Clinically significant change: favorable', 'No change or insignificant change', and then 'Clinically significant change (CSC): unfavorable. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame:
C2D4, C2D8, C5D8, C6D15
Reported as:
Number · Participants
Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
No change or insignificant change n=3,9,3,83837
CSC: unfavorable, n=3,9,3,80101
PrimaryMean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II

Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each participant across Cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), Baseline loge(platelet count) and part of study (part 1 or 2 of phase II). Only those participants available at indicated time points were analyzed (represented by n=X,X).

Time frame:
Day 1 (averaged across cycles 1 to 6)
Reported as:
Geometric mean · Giga (10^9) cells per liter (Gi/L)
Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II
Giga (10^9) cells per liter (Gi/L)PlaceboEltrombopag 100 mg
Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II193.34 ± 54.5246.20 ± 49.8
Statistical analysis
  • Placebo vs Eltrombopag 100 mg · ANCOVA · p = 0.103 · Percent difference: 21.1 · 95% CI -3.9 to 52.5
SecondaryAverage Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I

Pre-chemotherapy platelet count is defined for Cycle 1 as the platelet count (from central laboratory data) immediately preceding the first dose of chemotherapy within Cycle 1. For all subsequent cycles it is defined as the platelet count (from central laboratory data) immediately preceding, but limited to within 2 days prior to the first dose of chemotherapy at Day 1. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at the following time points: Group A; Days 1 and 8 of Cycles 1 to 6. Group B; Days 1, 8 and 15 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame:
C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1,C4D8, C4D15, C5D1,C5D8, C5D15, C6D1,C6D8 and C6D15
Reported as:
Mean · Giga (10^9) cells per liter (G cells/L)
Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I
Giga (10^9) cells per liter (G cells/L)21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
C1 D1, n=3,9,4,9239.3 ± 75.87244.8 ± 48.47223.8 ± 79.96207.7 ± 65.51
C1 D8, n=3,6,3,9180.7 ± 65.03143.8 ± 33.88144.0 ± 44.17135.6 ± 52.52
C1 D15, n=0,0,2, 6NA ± NANA ± NA135.0 ± 84.8597.5 ± 39.15
C2 D1, n=2,9,4,8443.0 ± 168.29545.8 ± 131.66284.8 ± 84.11473.3 ± 117.07
C2 D8, n=2,7,3,9221.0 ± 94.75335.6 ± 134.06163.3 ± 35.30333.0 ± 146.59
C2 D15, n=0,0,2,6NA ± NANA ± NA80.5 ± 0.71142.7 ± 63.14
C3 D1, n=2,5,2,7464.0 ± 36.77484.6 ± 188.16290.5 ± 180.31435.4 ± 145.57
C3 D8, n=2,6,2,5285.0 ± 39.60292.2 ± 161.11293.0 ± 199.40465.2 ± 260.20
C3 D15, n=0,0,2,5NA ± NANA ± NA92.0 ± 45.25183.4 ± 119.12
C4 D1, n=1,6,1,6298.0 ± NA394.7 ± 154.28609.0 ± NA388.3 ± 166.07
C4 D8, n=1,5,1,6261.0 ± NA249.8 ± 122.29335.0 ± NA366.5 ± 143.75
C4 D15, n=0,0,1,6NA ± NANA ± NA86.0 ± NA169.8 ± 120.56
C5 D1, n=1,2,1,4245.0 ± NA529.5 ± 340.12337.0 ± NA406.0 ± 174.89
C5 D8, n=1,1,1,4144.0 ± NA123.0 ± NA311.0 ± NA403.5 ± 195.31
C5 D15, n=0,0,1,4NA ± NANA ± NA75.0 ± NA140.5 ± 42.93
C6 D1, n=1,1,1,3512.0 ± NA123.0 ± NA440.0 ± NA360.3 ± 133.45
C6 D8, n=1,1,0,3251.0 ± NA137.0 ± NANA ± NA428.0 ± 210.71
C6 D15, n=0,0,1,2NA ± NANA ± NA113.0 ± NA101.0 ± 48.08
SecondaryAverage Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I

Within-subject platelet count for each participant was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the participant had data. The average within a treatment group was calculated by summing up the values from each participant within the treatment group and dividing it by the number of participants. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 2 to 6 are summarized. Blood samples were collected on Days 1 and 8 of Cycles 2 to 6 for Group A and on Days 1, 8 and 15 from Cycles 2 to 6 for Group B to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame:
Day 1 (averaged across Cycles 2 to 6), Day 8 (averaged across Cycles 2 to 6)
Reported as:
Mean · Giga (10^9) cells per liter (G cells/L)
Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I
Giga (10^9) cells per liter (G cells/L)21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
G+Cb, Day 1, n=1,3,0,0296.80 ± NA275.00 ± 144.253NA ± NANA ± NA
G+Cb, Day 8, n=1,3,0,0235.00 ± NA232.10 ± 77.329NA ± NANA ± NA
G+Cis, Day 1, n=2,6,0,0322.50 ± 82.731526.00 ± 86.408NA ± NANA ± NA
G+Cis, Day 8, n=2,6,0,0326.85 ± 119.006296.75 ± 119.342NA ± NANA ± NA
Gm, Day1, n=0,0,4,9NA ± NANA ± NA309.20 ± 123.133442.79 ± 114.593
Gm, Day8, n=0,0,4,10NA ± NANA ± NA204.20 ± 80.822355.09 ± 148.539
Gm, Day15, n=0,0,3,10NA ± NANA ± NA75.37 ± 18.292164.24 ± 94.905
SecondaryPlatelet Count Nadir for Each Chemotherapy Cycle in Phase I

Platelet nadir is defined as the lowest platelet count (from central laboratory data) reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 and 2, at Days 1, 4, 8, 15 and 17 of Cycle 3 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Giga (10^9) cells per liter (G cells/L)
Platelet Count Nadir for Each Chemotherapy Cycle in Phase I
Giga (10^9) cells per liter (G cells/L)21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Cycle 1, n=3,9,4,1030.67 ± 20.404106.56 ± 113.33860.50 ± 22.66499.00 ± 75.700
Cycle 2, n=2,9,4,1066.00 ± 9.899122.44 ± 115.794103.50 ± 62.952135.50 ± 73.951
Cycle 3, n=2,7,2,747.00 ± 4.24388.29 ± 71.80778.50 ± 43.134151.00 ± 111.946
Cycle 4, n=2,6,1,776.50 ± 4.95087.50 ± 79.17386.00 ± NA142.86 ± 91.908
Cycle 5, n=1,2,1,414.00 ± NA148.00 ± 182.43475.00 ± NA113.25 ± 34.683
Cycle 6, n=1,1,1,424.00 ± NA13.00 ± NA110.00 ± NA122.75 ± 63.163
SecondaryCentral Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I

The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 2 to 6. For 21-Day Cycle, the chemotherapy cycle consisted of 21 days and for 28-Day Cycle, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-Day Cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-Day Cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.

Time frame:
All assessments from Cycle 2 Day 1 to last assessment in Cycle 6
Reported as:
Mean · Giga (10^9) cells per liter (G cells/L)
Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I
Giga (10^9) cells per liter (G cells/L)21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg)28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I260.97 ± 67.581307.59 ± 95.110183.68 ± 55.366291.18 ± 99.718
SecondaryNumber of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count

As per the CTCAE version 4.0, par. with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; par. with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; par. with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and par. with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Par. experiencing thrombocytopenia (Platelets \<150Gi/L) at least once within a cycle are presented in the category title as n=X,X,X,X.

Time frame:
Cycle 1 to Cycle 6
Reported as:
Number · Participants
Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Grade 1, n=3,9,4,100213
Grade 2, n=3,9,4,100314
Grade 3, n=3,9,4,101110
Grade 4, n=3,9,4,101200
Grade 0 / None, n=3,9,4,101113
SecondaryMaximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts

Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for Group A was 21 days and for Group B was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.

Time frame:
Cycle 2 to Cycle 6
Reported as:
Mean · Days
Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts
Days21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts11.0 ± 4.2410.6 ± 5.6314.7 ± 7.7713.4 ± 5.06
SecondaryCentral Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Days
Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I
Days21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Cycle 1, n=3,9,4,1015.7 ± 0.5811.4 ± 5.5313.8 ± 6.1313.8 ± 4.73
Cycle 2, n=2,9,4,1015.0 ± 1.4112.9 ± 4.6814.0 ± 5.7219.2 ± 4.42
Cycle 3, n=2,7,2,715.0 ± 1.4112.9 ± 3.0223.5 ± 0.7117.6 ± 4.50
Cycle 4, n=2,6,1,714.0 ± 0.0013.5 ± 3.3314.0 ± NA17.4 ± 6.16
Cycle 5, n=1,2,1,415.0 ± NA11.5 ± 6.3614.0 ± NA21.5 ± 1.00
Cycle 6, n=1,1,1,416.0 ± NA14.0 ± NA23.0 ± NA15.5 ± 5.20
SecondaryTime to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. Time to recovery (TR) (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22, and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Days
Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts
Days21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
TR(<100Gi/L to >=100Gi/L), Cycle 1, n=3,6,4,75.3 ± 0.587.2 ± 2.567.0 ± 0.007.7 ± 2.87
TR(<100Gi/L to >=100Gi/L), Cycle 2, n=2,5,3,46.5 ± 2.126.6 ± 3.656.0 ± 4.007.0 ± 5.10
TR(<100Gi/L to >=100Gi/L), Cycle 3, n=1,4,0,27.0 ± NA8.5 ± 3.70NA ± NA6.0 ± 1.41
TR(<100Gi/L to >=100Gi/L), Cycle 4, n=1,4,1,22.0 ± NA6.5 ± 5.2014.0 ± NA5.0 ± 2.83
TR(<100Gi/L to >=100Gi/L), Cycle 5, n=1,1,1,15.0 ± NA5.0 ± NA9.0 ± NA7.0 ± NA
TR(<100Gi/L to >=100Gi/L), Cycle 6, n=0,1,0,0NA ± NA7.0 ± NANA ± NANA ± NA
TR(<150Gi/L to >=150Gi/L), Cycle 1, n=3,7,4,85.3 ± 0.587.6 ± 2.577.0 ± 0.008.5 ± 3.46
TR(<150Gi/L to >=150Gi/L), Cycle 2, n=2,4,3,56.5 ± 2.127.8 ± 2.999.0 ± 4.369.4 ± 4.28
TR(<150Gi/L to >=150Gi/L), Cycle 3, n=1,6,1,57.0 ± NA8.0 ± 2.977.0 ± NA6.2 ± 1.10
TR(<150Gi/L to >=150Gi/L), Cycle 4, n=1,4,1,48.0 ± NA7.8 ± 4.2714.0 ± NA8.3 ± 3.95
TR(<150Gi/L to >=150Gi/L), Cycle 5, n=1,0,1,35.0 ± NANA ± NA14.0 ± NA4.7 ± 2.52
TR(<150Gi/L to >=150Gi/L), Cycle 6, n=0,0,1,0NA ± NANA ± NA5.0 ± NANA ± NA
SecondaryDose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I

Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: Cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within Cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on electronic case report form (eCRF).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Dose Intensity (%)
Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I
Dose Intensity (%)21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
G+Cis, Gemcitabine, Cycle 1, n=2,5,0,0100.0 ± 0.0099.8 ± 0.45NA ± NANA ± NA
G+Cis, Gemcitabine, Cycle 2, n=1,5,0,0100.0 ± NA92.8 ± 24.83NA ± NANA ± NA
G+Cis, Gemcitabine, Cycle 3, n=1,4,0,0100.0 ± NA104.3 ± 8.50NA ± NANA ± NA
G+Cis, Gemcitabine, Cycle 4, n=1,3,0,0100.0 ± NA83.3 ± 28.87NA ± NANA ± NA
G+Cis, Cisplatin, Cycle 1, n=2,6,0,0100.0 ± 0.00100.3 ± 1.03NA ± NANA ± NA
G+Cis, Cisplatin, Cycle 2, n=1,6,0,0100.0 ± NA102.8 ± 6.05NA ± NANA ± NA
G+Cis, Cisplatin, Cycle 3, n=1,5,0,0100.0 ± NA93.8 ± 24.34NA ± NANA ± NA
G+Cis, Cisplatin, Cycle 4, n=1,4,0,0100.0 ± NA100.3 ± 0.96NA ± NANA ± NA
G+Cis, Cisplatin, Cycle 5, n=0,1,0,0NA ± NA50 ± NANA ± NANA ± NA
G+Cb, Gemcitabine, Cycle 1, n=1,2,0,099.0 ± NA100.0 ± 0.00NA ± NANA ± NA
G+Cb, Gemcitabine, Cycle 2, n=1,2,0,099.0 ± NA88.5 ± 17.68NA ± NANA ± NA
G+Cb, Gemcitabine, Cycle 3, n=1,2,0,099.0 ± NA100.0 ± 0.00NA ± NANA ± NA
G+Cb, Gemcitabine, Cycle 4, n=1,2,0,049.0 ± NA99.5 ± 0.71NA ± NANA ± NA
G+Cb, Gemcitabine, Cycle 5, n=1,1,0,099.0 ± NA74.0 ± NANA ± NANA ± NA
G+Cb, Gemcitabine, Cycle 6, n=1,1,0,099.0 ± NA74.0 ± NANA ± NANA ± NA
G+Cb, Carboplatin, Cycle 1, n=1,3,0,0101.0 ± NA88.7 ± 14.05NA ± NANA ± NA
G+Cb, Carboplatin, Cycle 2, n=1,3,0,0100.0 ± NA103.0 ± 5.20NA ± NANA ± NA
G+Cb, Carboplatin, Cycle 3, n=1,2,0,093.0 ± NA105.0 ± 5.66NA ± NANA ± NA
G+Cb, Carboplatin, Cycle 4, n=1,2,0,091.0 ± NA107.5 ± 2.12NA ± NANA ± NA
G+Cb, Carboplatin, Cycle 5, n=1,1,0,0100.0 ± NA71.0 ± NANA ± NANA ± NA
G+Cb, Carboplatin, Cycle 6, n=1,1,0,087.0 ± NA79.0 ± NANA ± NANA ± NA
Gemcitabine, Cycle 1, n=0,0,1,7NA ± NANA ± NA100.0 ± NA94.7 ± 6.75
Gemcitabine, Cycle 2, n=0,0,1,7NA ± NANA ± NA100.0 ± NA85.0 ± 17.48
Gemcitabine, Cycle 3, n=0,0,1,4NA ± NANA ± NA100.0 ± NA79.5 ± 21.44
Gemcitabine, Cycle 4, n=0,0,0,4NA ± NANA ± NANA ± NA94.8 ± 4.11
Gemcitabine, Cycle 5, n=0,0,0,3NA ± NANA ± NANA ± NA93.7 ± 3.79
Gemcitabine, Cycle 6, n=0,0,0,3NA ± NANA ± NANA ± NA72.7 ± 17.01
SecondaryNumber of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I

Any delay in a scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants.

Time frame:
All time on chemotherapy treatment
Reported as:
Number · Participants
Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I
Participants21-Day Cycle Placebo21-Day Cycle Eltrombopag 100 mg28-Day Cycle Placebo28-Day Cycle Eltrombopag 100 mg
Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I1221
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II

AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.

Time frame:
From first dose of investigational product (IP) until 30 days after discontinuation of IP (Longer for AEs related to study participation)
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II
ParticipantsPlaceboEltrombopag 100 mg
Any AE Pre Therapy01
Any SAE Pre Therapy00
Any AE On Therapy+30 days2348
Any SAE On Therapy+30 days1216
Any AE Post Therapy42
Any SAE Post Therapy21
Blood/lymphatic system disorders On-therapy+30 day2140
Thrombocytopenia On-therapy+30 days1119
Anemia On-therapy+30 days1626
Neutopenia On-therapy+30 days1321
Gastrointestinal disorders On-therapy+30 days1225
Blood Creatinine increased On-therapy+30 days32
Vascular discorders On-therapy+30 days26
Cardiac disorders On-therapy+30 days13
Pulmonary embolism On-therapy+30 days01
Portal vein thrombosis On-therapy+30 days10
Deaths On-therapy+30 days913
SecondaryNumber of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II

The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were further classified into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline is defined as the Day 1 assessment or the latest possible screening assessment. Across Cycles 1-6 included all assessments after first dose of chemotherapy up to the end of Cycle 6. Data exclused for participants taking drugs that affect platelet function or anticoagulants, from the time that the medication was started.

Time frame:
Screening, Day -5, Day 1 and 8 of Cycles 1 to 6 of 21-day cycle schedule, Day 1, 8 and 15 of cycles 1 to 6 of 28-day schedule, treatment withdrawal and 30-day follow-up
Reported as:
Number · Participants
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II
ParticipantsPlaceboEltrombopag 100 mg
Grade 01134
Grade 110
Grade 200
Grade 300
Grade 401
SecondaryNumber of Participants Requiring a Platelet Transfusion in Phase II

Platelet transfusion was used as a rescue medication for the treatment of thrombocytopenia. Number of participants requiring a platelet transfusion during Cycles 1-6 was summarized and compared between treatment groups using a logistic regression model adjusted for cycle duration. Each cycle included assessments starting at Day 1 of the cycle.

Time frame:
Screening, Day -5, throughout cycles 1 to 6 and up to 30 days after IP discontinuation
Reported as:
Number · Participants
Number of Participants Requiring a Platelet Transfusion in Phase II
ParticipantsPlaceboEltrombopag 100 mg
Cycle 104
Cycle 223
Cycle 302
Cycle 411
Cycle 500
Cycle 600
SecondaryNumber of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

Any delay in scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants. Number of participants with any delay in dose during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only those participants who actually received chemotherapy are included for the cisplatin and carboplatin components and all participants are included for the gemcitabine components (represented by n=X,X in the category titles).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Number · Participants
Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II
ParticipantsPlaceboEltrombopag 100 mg
Gemcitabine, 21-day cycle, n=11,2257
Carboplatin, 21-day cycle, n=4,1245
Cisplatin, 21-day cycle, n=7,912
Gemcitabine, 28-day cycle, n=12,3044
SecondaryNumber of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

Dose reductions are required following potential drug-related toxicities. Number of participants with any dose reduction during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only participants who actually received chemotherapy were included for the cisplatin and carboplatin components. All participants were included for the gemcitabine components.

Time frame:
Cycle 1 to Cycle 6
Reported as:
Number · Participants
Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II
ParticipantsPlaceboEltrombopag 100 mg
Gemcitabine, 21-day cycle, n=11,2276
Carboplatin, 21-day cycle, n=4,1222
Cisplatin, 21-day cycle, n=7,903
Gemcitabine, 28-day cycle, n=12,3088
SecondaryDose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II

Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on eCRF. The average chemotherapy dose intensity at Day 1 across Cycles 1 to 6, Day 8 across Cycles 1 to 6 and Day 15 across Cycles 1 to 6 was summarized and compared between treatment groups using an ANCOVA model adjusted for cycle duration and part of the study.

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Dose Intensity (%)
Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II
Dose Intensity (%)PlaceboEltrombopag 100 mg
Cycle 1, n=23,4896.6 ± 10.6597.9 ± 6.19
Cycle 2, n=19,37113.1 ± 33.9197.8 ± 24.99
Cycle 3, n=13,26102.6 ± 42.2098.7 ± 35.77
Cycle 4, n=11,1996.6 ± 27.6590.7 ± 30.00
Cycle 5, n=6,12102.2 ± 31.8881.3 ± 25.39
Cycle 6, n=5,784.4 ± 21.9265.2 ± 25.48
Cycle 1-6, n=23,4998.5 ± 18.2694.6 ± 15.71
SecondaryNumber of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II

Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included Hemoglobin (Hb) increased, Anemia, Lymphocyte count (Lym), platelet count, White Blood Cell count (WBC) and Total Absolute Neutrophil Count (Total ANC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. participants with missing Baseline value were assumed to have normal Baseline value. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame:
After baseline (C1D1), on-treatment and 30 day follow-up
Reported as:
Number · Participants
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II
ParticipantsPlaceboEltrombopag 100 mg
Hb (Increased), Grade 0, n=23,522352
Hb (Increased), Grade 1, n=23,5200
Hb (Increased), Grade 2, n=23,5200
Hb (Increased), Grade 3, n=23,5200
Hb (Increased), Grade 4, n=23,5200
Hb (Anemia), Grade 0, n=23,5204
Hb (Anemia), Grade 1, n=23,52416
Hb (Anemia), Grade 2, n=23,521316
Hb (Anemia), Grade 3, n=23,52616
Hb (Anemia), Grade 4, n=23,5200
Lym (Increased), Grade 0, n=23,522247
Lym (Increased), Grade 1, n=23,5200
Lym (Increased), Grade 2, n=23,5212
Lym (Increased), Grade 3, n=23,5201
Lym (Increased), Grade 4, n=23,5200
Lym (Decreased), Grade 0, n=23,5217
Lym (Decreased), Grade 1, n=23,52310
Lym (Decreased), Grade 2, n=23,52814
Lym (Decreased), Grade 3, n=23,52916
Lym (Decreased), Grade 4, n=23,5223
Total ANC, Grade 0, n=23,52416
Total ANC, Grade 1, n=23,5214
Total ANC, Grade2, n=23,52317
Total ANC, Grade 3, n=23,521010
Total ANC, Grade 4, n=23,5253
Platelet count, Grade 0, n=23,5207
Platelet count, Grade 1, n=23,5249
Platelet count, Grade 2, n=23,5239
Platelet count, Grade 3, n=23,52615
Platelet count, Grade 4, n=23,521012
WBC count, Grade 0, n=23,52414
WBC count, Grade 1, n=23,52310
WBC count, Grade 2, n=23,52817
WBC count, Grade 3, n=23,52611
WBC count, Grade 4, n=23,5220
SecondaryNumber of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II

Clinical chemistry laboratory parameters with a related CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Worst-case grade change of the laboratory parameters at anytime post-Baseline is presented as "Any grade increase", "Increase to Grade 3 or Grade 4". Clinical chemistry laboratory parameters included Albumin (Al), creatinine, AST, ALT, ALP, TB, Calcium hypercalcemia (CaHy)/hypocalcemia (CaHo), Glucose hyperglycemia (GluHy)/hypoglycemia (GluHo), Potassium hypernatremia (KHy)/hyponatremia (KHo) and Sodium hypernatremia (NaHy)/hyponatremia (NaHo). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame:
After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up
Reported as:
Number · participants
Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II
participantsPlaceboEltrombopag 100 mg
Al, Any grade increase, n=23,511022
Al, Increase to Grade 3, n=23,5102
Al, Increase to Grade 4, n=23,5100
ALP, Any grade increase, n=23,521116
ALP, Increase to Grade 3, n=23,5212
ALP, Increase to Grade 4, n=23,5200
ALT, Any grade increase, n=23,521216
ALT, Increase to Grade 3, n=23,5232
ALT, Increase to Grade 4, n=23,5200
AST, Any grade increase, n=23,521115
AST, Increase to Grade 3, n=23,5232
AST, Increase to Grade 4, n=23,5200
TB, Any grade increase, n=23,52511
TB, Increase to Grade 3, n=23,5232
TB, Increase to Grade 4, n=23,5200
CaHy, Any grade increase, n=23,5101
CaHy, Increase to Grade 3, n=23,5100
CaHy, Increase to Grade 4, n=23,5100
CaHo, Any grade increase, n=23,51310
CaHo, Increase to Grade 3, n=23,5112
CaHo, Increase to Grade 4, n=23,5100
Creatinine, Any grade increase, n=23,52511
Creatinine, Increase to Grade 3, n=23,5210
Creatinine, Increase to Grade 4, n=23,5200
GluHy, Any grade increase, n=23,521331
GluHy, Increase to Grade 3, n=23,5223
GluHy, Increase to Grade 4, n=23,5200
GluHo, Any grade increase, n=23,5224
GluHo, Increase to Grade 3, n=23,5200
GluHo, Increase to Grade 4, n=23,5210
NaHy, Any grade increase, n=23,5202
NaHy, Increase to Grade 3, n=23,5200
NaHy, Increase to Grade 4, n=23,5200
NaHo, Any grade increase, n=23,52415
NaHo, Increase to Grade 3, n=23,5211
NaHo, Increase to Grade 4, n=23,5200
KHy, Any grade increase, n=23,52410
KHy, Increase to Grade 3, n=23,5211
KHy, Increase to Grade 4, n=23,5200
KHo, Any grade increase, n=23,52511
KHo, Increase to Grade 3, n=23,5214
KHo, Increase to Grade 4, n=23,5201
SecondaryNumber of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II

Number of participants with at least 1 assessment of change from Baseline in creatinine, with increase \>=26.5 UMOL/L are presented. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of IP.

Time frame:
After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up
Reported as:
Number · participants
Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II
participantsPlaceboEltrombopag 100 mg
Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II511
SecondaryNumber of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II

ECOG-Zubrod scores for the Performance Status were defined as follows: 0: Fully active, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: Ambulatory and capable of all self-care but unable to carry out any work activities, 3: Capable of only limited self-care, 4: Completely disabled, 5 and Unknown: Dead. The data is presented for the participants with the ECOG performance score at different time points during the study. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame:
Screening, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1 and C17D1
Reported as:
Number · participants
Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II
participantsPlaceboEltrombopag 100 mg
Screening, Score 0, n=23,52319
Screening, Score 1, n=23,521932
Screening, Score 2, n=23,5211
C1D1, Score 0, n=23,49420
C1D1, Score 1, n=23,491728
C1D1, Score 2, n=23,4901
C1D1, Unknown, n=23,4920
C2D1, Score 0, n=19,36416
C2D1, Score 1, n=19,361318
C2D1, Score 2, n=19,3622
C3D1, Score 0, n=13,2739
C3D1, Score 1, n=13,27916
C3D1, Score 2, n=13,2712
C4D1, Score 0, n=11,1948
C4D1, Score 1, n=11,19710
C4D1, Score 2, n=11,1901
C5D1, Score 0, n=6,1225
C5D1, Score 1, n=6,1246
C5D1, Score 2, n=6,1201
C6D1, Score 0, n=6,723
C6D1, Score 1, n=6,744
C7D1, Score 0, n=3,210
C7D1, Score 1, n=3,222
C8D1, Score 0, n=2,110
C8D1, Score 1, n=2,111
C9D1, Score 1, n=2,121
C10D1, Score1 n=2,020
C11D1, Score 1, n=2,010
C11D1, Score 2, n=2,010
C12D1, Score 1, n=2,020
C13D1, Score 0, n=2,010
C13D1, Score 1, n=2,010
C14D1, Score 0, n=2,010
C14D1, Score 1, n=2,010
C15D1, Score 1, n=2,020
C16D1, Score 0, n=1,010
C17D1, Score 2, n=1,010
SecondaryNumber of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II

A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and 2 to 6 hours post-dose on C1D4. Change in ECG findings were categorized as 'Clinically significant change (CSC): favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of investigational product. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame:
C1D4
Reported as:
Number · participants
Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II
participantsPlaceboEltrombopag 100 mg
CSC favorable, n=22,4502
No change or insignificant change, n=22,452042
CSC: unfavorable, n=22,4521
SecondaryMean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 8 scheduled platelet count.

Time frame:
Day 8 (averaged across cycles 1 to 6)
Reported as:
Geometric mean · Giga (10^9) cells per liter (G cells/L)
Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II
Giga (10^9) cells per liter (G cells/L)PlaceboEltrombopag 100 mg
Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II162.18 ± 74.2180.65 ± 59.1
Statistical analysis
  • Placebo vs Eltrombopag 100 mg · ANCOVA · p = 0.407 · Percent difference: 12.9 · 95% CI -15.6 to 51.1
SecondaryMean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 15 scheduled platelet count.

Time frame:
Day 15 (averaged across cycles 1 to 6)
Reported as:
Geometric mean · Giga (10^9) cells per liter (G cells/L)
Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II
Giga (10^9) cells per liter (G cells/L)PlaceboEltrombopag 100 mg
Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II95.10 ± 23.395.29 ± 52.1
Statistical analysis
  • Placebo vs Eltrombopag 100 mg · ANCOVA · p = 0.802 · Percent difference: -4.4 · 95% CI -33.5 to 37.4
SecondaryMean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II

Within-subject platelet count for each par. was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the par. had data. The average within a treatment group was calculated by summing up the values from each par. within the treatment 21-day cycle dividing it by the number of par. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 1 to 6 are summarized. Blood samples were collected on Day 1 and 8 of Cycles 1 to 6 for 21-day cycle and on Day 1, 8 and 15 from Cycles 1 to 6 for 28-day cycle to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame:
Day 1, Day 8, Day 15 (all averaged across cycles 1 to 6)
Reported as:
Mean · Giga (10^9) cells per liter (G cells/L)
Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II
Giga (10^9) cells per liter (G cells/L)PlaceboEltrombopag 100 mg
Day1, n=23,48221.0 ± 128.23272.9 ± 120.92
Day 8, n=20,42201.0 ± 143.75207.4 ± 110.93
Day 15, n=9,2297.5 ± 24.82106.7 ± 54.73
SecondaryPlatelet Count Nadir for Each Chemotherapy Cycle in Phase II

Platelet nadir is defined as the lowest platelet count reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Day 1, Day 4, Day 8, Day 15 and Day 17 of Cycles 1 to 6. 28-day cycle; Day 1, Day 4, Day 8, Day 15, Day 22, Day 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Giga (10^9) cells per liter (G cells/L)
Platelet Count Nadir for Each Chemotherapy Cycle in Phase II
Giga (10^9) cells per liter (G cells/L)PlaceboEltrombopag 100 mg
Cycle 1, n=23,4868.3 ± 47.7477.2 ± 76.43
Cycle 2, n=19,3761.5 ± 35.8268.5 ± 48.92
Cycle 3, n=13,2671.6 ± 53.8084.7 ± 60.03
Cycle 4, n=11, 1989.7 ± 116.7386.9 ± 56.11
Cycle 5, n=6,1151.7 ± 12.2383.0 ± 58.63
Cycle 6, n=5,569.6 ± 62.76136.6 ± 151.88
SecondaryAverage Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II

The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 1 to 6. Blood samples were collected to estimate platelet count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.

Time frame:
All assessments from Cycle 1 Day 1 to last assessment in Cycle 6
Reported as:
Mean · Giga (10^9) cells per liter (G cells/L)
Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II
Giga (10^9) cells per liter (G cells/L)PlaceboEltrombopag 100 mg
Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II153.00 ± 96.079189.48 ± 79.583
SecondaryNumber of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II

As per the CTCAE version 4.0, participants with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; participants with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; participants with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and participants with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Participants experiencing thrombocytopenia(Platelets \<150Gi/L) at least once within cycle are presented in the category title as n=X,X.

Time frame:
Cycle 1 to Cycle 6
Reported as:
Number · Participants
Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II
ParticipantsPlaceboEltrombopag 100 mg
Grade 149
Grade 239
Grade 3815
Grade 4812
None05
SecondaryMaximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II

Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for 21-day cycle was 21 days and for 28-day cycle was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Days
Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II
DaysPlaceboEltrombopag 100 mg
Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II32.6 ± 20.3123.5 ± 18.68
SecondaryTime Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Days
Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II
DaysPlaceboEltrombopag 100 mg
Cycle 1, n=23,4814.7 ± 4.8515.7 ± 6.12
Cycle 2, n=19,3715.1 ± 4.4115.4 ± 3.62
Cycle 3, n=13,2615.8 ± 5.6414.3 ± 4.76
Cycle 4, n=11,1915.4 ± 5.4814.7 ± 5.19
Cycle 5, n=6,1115.5 ± 6.3813.8 ± 4.45
Cycle 6, n=5,513.6 ± 7.3710.4 ± 6.31
Cycle 7,n=2,215.0 ± 0.007.5 ± 0.71
Cycle 8, n=2,112.5 ± 3.548.0 ± NA
Cycle 9, n=2,012.5 ± 3.54NA ± NA
SecondaryTime to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. TR (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. Blood samples were collected to estimate platelet count at: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22, and 24of Cycles 1 to 6. Time to recover censored if platelet count did not return to \>=100/150 Gi/L. Censored results are excluded from calculation of summary statistics. Only those participants available at indicated time points were analyzed (represented by n=X, X).

Time frame:
Cycle 1 to Cycle 6
Reported as:
Mean · Days
Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II
DaysPlaceboEltrombopag 100 mg
TR(<100Gi/L to >=100Gi/L), Cycle 1, n=17, 328.1 ± 3.158.5 ± 3.70
TR(<150Gi/L to >=150Gi/L), Cycle 1, n=12, 299.3 ± 3.899.1 ± 3.26
TR(<100Gi/L to >=100Gi/L), Cycle 2, n=13, 249.9 ± 3.648.3 ± 2.56
TR(<150Gi/L to >=150Gi/L), Cycle 2, n=11, 2110.5 ± 4.509.0 ± 3.31
TR(<100Gi/L to >=100Gi/L), Cycle 3, n=9, 1210.1 ± 5.018.8 ± 3.16
TR(<150Gi/L to >=150Gi/L), Cycle 3, n=7, 1410.4 ± 5.749.6 ± 3.43
TR(<100Gi/L to >=100Gi/L), Cycle 4, n=8, 1010.0 ± 5.6310.9 ± 4.77
TR(<150Gi/L to >=150Gi/L), Cycle 4, n=5, 1110.2 ± 6.6510.6 ± 5.39
TR(<100Gi/L to >=100Gi/L), Cycle 5, n=5,67.8 ± 1.108.8 ± 4.79
TR(<150Gi/L to >=150Gi/L), Cycle 5, n=2,48.0 ± 0.007.3 ± 1.50
TR(<100Gi/L to >=100Gi/L), Cycle 6, n=2,210.5 ± 6.368.5 ± 0.71
TR(<150Gi/L to >=150Gi/L), Cycle 6, n=2,110.5 ± 6.368.0 ± NA
TR(<100Gi/L to >=100Gi/L), Cycle 7, n=1,115.0 ± NA22.0 ± NA
TR(<150Gi/L to >=150Gi/L), Cycle 7, n=1,115.0 ± NA22.0 ± NA
TR(<100Gi/L to >=100Gi/L), Cycle 8, n=1,114.0 ± 1.4120.0 ± NA
TR(<150Gi/L to >=150Gi/L), Cycle 8, n=1,015.0 ± NANA ± NA
TR(<100Gi/L to >=100Gi/L), Cycle 9, n=2,14.0 ± 11.31NA ± NA
TR(<150Gi/L to >=150Gi/L), Cycle 9, n=0,NA ± NANA ± NA

Adverse events

Collected over AEs and SAEs were collected from Cycle 1, Day 1 for Phase I; and from the time the first dose of investigational product (IP) is administered for Phase II; up to 30 days following discontinuation of IP.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I: 21-Day Cycle Placebo—1/3 (33.3%)3/3 (100%)
Phase I: 21-Day Cycle Eltrombopag—5/9 (55.6%)9/9 (100%)
Phase I: 28-Day Cycle Placebo—1/4 (25%)4/4 (100%)
Phase I: 28-Day Cycle Eltrombopag 100 mg—2/10 (20%)10/10 (100%)
Phase II: Placebo—13/23 (56.5%)22/23 (95.7%)
Phase II: Eltrombopag—17/52 (32.7%)47/52 (90.4%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventPhase I: 21-Day Cycle PlaceboPhase I: 21-Day Cycle EltrombopagPhase I: 28-Day Cycle PlaceboPhase I: 28-Day Cycle Eltrombopag 100 mgPhase II: PlaceboPhase II: Eltrombopag
PneumoniaInfections and infestations1/30/90/40/100/233/52
PneumonitisRespiratory, thoracic and mediastinal disorders1/30/90/40/100/231/52
HaemoptysisRespiratory, thoracic and mediastinal disorders1/30/90/40/100/230/52
Pleural effusionRespiratory, thoracic and mediastinal disorders0/30/91/40/100/231/52
OliguriaRenal and urinary disorders0/30/91/40/100/230/52
Deep vein thrombosisVascular disorders0/32/90/40/100/230/52
NauseaGastrointestinal disorders0/31/90/40/100/231/52
VomitingGastrointestinal disorders0/31/90/40/100/231/52
Device damageGeneral disorders0/31/90/40/100/230/52
CholangitisHepatobiliary disorders0/31/90/40/100/230/52
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPhase I: 21-Day Cycle PlaceboPhase I: 21-Day Cycle EltrombopagPhase I: 28-Day Cycle PlaceboPhase I: 28-Day Cycle Eltrombopag 100 mgPhase II: PlaceboPhase II: Eltrombopag
NeutropeniaBlood and lymphatic system disorders3/35/92/46/1013/2321/52
ThrombocytopeniaBlood and lymphatic system disorders3/33/94/45/1010/2318/52
AnaemiaBlood and lymphatic system disorders1/34/93/45/1015/2324/52
LeukopeniaBlood and lymphatic system disorders2/32/92/43/102/239/52
ThrombocytosisBlood and lymphatic system disorders2/32/91/42/102/234/52
NauseaGastrointestinal disorders1/36/91/41/102/2310/52
FatigueGeneral disorders1/31/92/43/103/2313/52
Oedema peripheralGeneral disorders0/31/92/42/101/235/52
PyrexiaGeneral disorders1/31/92/40/104/233/52
DizzinessNervous system disorders0/30/92/41/102/231/52

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Phase I: 21-Day Cycle PlaceboPhase I: 21-Day Cycle Eltrombopag 100 mgPhase I: 28-Day Cycle PlaceboPhase I: 28-Day Cycle Eltrombopag 100 mgPhase II: PlaceboPhase II: Eltrombopag 100 mgTotal
Mean53.3 ± 3.7953.8 ± 11.2761.8 ± 22.8265.6 ± 8.4164.4 ± 9.9666.3 ± 8.9864.1 ± 10.56
Sex: Female, Male
Sex: Female, Male(Participants)Phase I: 21-Day Cycle PlaceboPhase I: 21-Day Cycle Eltrombopag 100 mgPhase I: 28-Day Cycle PlaceboPhase I: 28-Day Cycle Eltrombopag 100 mgPhase II: PlaceboPhase II: Eltrombopag 100 mgTotal
Female1733132350
Male2217102951
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase I: 21-Day Cycle PlaceboPhase I: 21-Day Cycle Eltrombopag 100 mgPhase I: 28-Day Cycle PlaceboPhase I: 28-Day Cycle Eltrombopag 100 mgPhase II: PlaceboPhase II: Eltrombopag 100 mgTotal
African American/African Heritage1100103
White2838225295
Central/South Asian Heritage0010001
Japanese/East Asian Heritage/South East Asian0002002
08

Study locations

86 sites
  • GSK Investigational Site
    Sedona, Arizona 86336, United States
  • GSK Investigational Site
    Hot Springs, Arkansas 71913, United States
  • GSK Investigational Site
    Rancho Cucamonga, California 91730, United States
  • GSK Investigational Site
    Norwich, Connecticut 06360, United States
  • GSK Investigational Site
    Jacksonville, Florida 32256, United States
  • GSK Investigational Site
    New Port Richey, Florida 34655, United States
  • GSK Investigational Site
    Rome, Georgia 30165, United States
  • GSK Investigational Site
    Savannah, Georgia 31405, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Bethesda, Maryland 20817, United States
  • GSK Investigational Site
    Rockville, Maryland 20850, United States
  • GSK Investigational Site
    Columbia, Missouri 65201, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89169, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 08003, United States
  • GSK Investigational Site
    Albany, New York 12206, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27403, United States
  • GSK Investigational Site
    Bend, Oregon 97701, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19106, United States
  • GSK Investigational Site
    Wynnewood, Pennsylvania 19096, United States
  • GSK Investigational Site
    Providence, Rhode Island 02903, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
  • GSK Investigational Site
    Greenville, South Carolina 29605, United States
  • GSK Investigational Site
    Arlington, Texas 76014, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Bedford, Texas 76022, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    San Antonio, Texas 78217, United States
  • GSK Investigational Site
    Tyler, Texas 75702, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Edmunds, Washington 98026, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Vancouver, Washington 98684, United States
  • GSK Investigational Site
    Yakima, Washington 98902, United States
  • GSK Investigational Site
    Charleroi, 6000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Libramont, 6800, Belgium
  • GSK Investigational Site
    Namur, 5000, Belgium
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Olomouc, 775 20, Czech Republic
  • GSK Investigational Site
    Praha 10, 100 00, Czech Republic
  • GSK Investigational Site
    Praha 5, 150 06, Czech Republic
  • GSK Investigational Site
    Helsinki, 00290, Finland
  • GSK Investigational Site
    Tampere, 33520, Finland
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Augsburg, Bayern 86150, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80335, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81241, Germany
  • GSK Investigational Site
    Goslar, Niedersachsen 38642, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30171, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01127, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Berlin, 14169, Germany
  • GSK Investigational Site
    Athens, 115 27, Greece
  • GSK Investigational Site
    Athens, 115 28, Greece
  • GSK Investigational Site
    Heraklion, Crete, 71100, Greece
  • GSK Investigational Site
    Thessaloniki, 564 29, Greece
  • GSK Investigational Site
    Budapest, 1529, Hungary
  • GSK Investigational Site
    Győr, 9022, Hungary
  • GSK Investigational Site
    Kaposvár, 7400, Hungary
  • GSK Investigational Site
    Törökbálint, Hungary
  • GSK Investigational Site
    Zalaegerszeg, 8900, Hungary
  • GSK Investigational Site
    Madurai, 625107, India
  • GSK Investigational Site
    Pune, 411001, India
  • GSK Investigational Site
    Pune, 411004, India
  • GSK Investigational Site
    Dublin, 4, Ireland
  • GSK Investigational Site
    Dublin, 7, Ireland
  • GSK Investigational Site
    Tallaght, Dublin, 24, Ireland
  • GSK Investigational Site
    Ashkelon, 78306, Israel
  • GSK Investigational Site
    Haifa, 34362, Israel
  • GSK Investigational Site
    Jerusalem, 91031, Israel
  • GSK Investigational Site
    Kfar Saba, 44281, Israel
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
  • GSK Investigational Site
    Zrifin, 70300, Israel
  • GSK Investigational Site
    Modena, Emilia-Romagna 41100, Italy
  • GSK Investigational Site
    Aviano (PN), Friuli-Venezia-Giulia 33081, Italy
  • GSK Investigational Site
    Milano, Lombardia 20133, Italy
  • GSK Investigational Site
    Sassari, Sardegna 07100, Italy
  • GSK Investigational Site
    Pisa, Toscana 56126, Italy
  • GSK Investigational Site
    Bialystok, 15-540, Poland
  • GSK Investigational Site
    Konin, 62-500, Poland
  • GSK Investigational Site
    Olsztyn, 10-357, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Poznan, 61-866, Poland
09

References and documents

Publications

  • Winer ES, Safran H, Karaszewska B, Richards DA, Hartner L, Forget F, Ramlau R, Kumar K, Mayer B, Johnson BM, Messam CA, Mostafa Kamel Y. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med. 2015 Jan;4(1):16-26. doi: 10.1002/cam4.326. Epub 2014 Aug 28. PubMed 25165041 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jan 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2010
First posted
Jun 22, 2010
Start
Jun 2010
Primary completionActual
Jan 2015
CompletionActual
Mar 2015
Results first posted
Apr 18, 2016
Last update
Apr 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01147809
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Jun 2010
Primary completion
Jan 2015
Completion
Mar 2015
Results posted
Apr 18, 2016
Last update
Apr 18, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion